Cyclacel (NASDAQ: CYCC), a biopharmaceutical company developing innovative medicines based on cancer cell biology, has closed an underwritten public offering of 2,078,214 shares of its common stock, including 271,071 additional shares per the full exercise of the over-allotment option granted to the underwriters. Cyclacel secured approximately $14.5 million in gross proceeds, with each of the shares sold at the public offering price of $7.00. The company intends to use the proceeds from the offering to support its growth strategy, as well as for working capital and general corporate purposes, including research and development expenses and capital expenditures. Roth Capital Partners acted as co-manager for the offering.
To view the full press release, visit https://ibn.fm/8l41b
About Cyclacel Pharmaceuticals Inc.
Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program CYC140, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel’s strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For more information about the company, visit www.Cyclacel.com.
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.